TRThomas Renne

Thomas Renne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Renne has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determinants of functional burden pleiotropy and gene dosage responses across human traits

    by Sayeh Kazem, Kuldeep Kumar, Jane Yang, Florian Benitiere, Guillaume Huguet, Josephine Mollon, Thomas Renne, Laura M. Schultz, Emma E. M. Knowles, Worrawat Engchuan, et al.

  • Open Access

    Genetic and Cortical Cell-Type Liability Architecture of Autism

    by Thomas Renne, Florian Benitière, Cecile Poulain, Alma Dubuc, Vincent Bourque, Guillaume Huguet, Tomasz Nowakowski, Sebastien Jacquemont

    Autism Spectrum Disorders (ASD) can result from rare genetic variants interfering with brain development. Whether their effects converge on specific cortical cell types remains unresolved. Previous studies have focused on a narrow set of high-confidence ASD (hcASD) genes, which were enriched in neuronal cell types during prenatal development. By contrast, studies of postnatal cerebral cortex have repeatedly associated ASD with transcriptional changes in both neurons and glia. To comprehensively map ASD genetic liability across cortical cell types, we conducted a functional genetic burden analysis with 124,416 individuals, including ASD probands and unaffected family members. We examined six classes of rare gene-disrupting variants aggregated across a complete spectrum of transcriptomic cell types of the human prefrontal cortex throughout development. We show that cellular liabilities in ASD delineate a broad and developmentally dynamic architecture. Likewise, we uncover high dependency on classes of variants with Loss-of-Function (LoF) and de novo linked to prenatal cells, while duplications, missense, and inherited variants increase liability through postnatal and glial cell types. Notably, inherited LoF variants uncover the contribution of microglia to ASD liability, also supported by transcriptomic evidence from postmortem ASD brains. Finally, we show that overall, variants disrupting genes differentially expressed in postmortem ASD brains significantly contribute to ASD liability, demonstrating convergence between disrupted transcriptomes and genetic liability. Together, our study offers an integrative, cell-type-aware framework for interpreting ASD risk genetics.

  • Open Access

    Genetic and Cortical Cell-Type Liability Architecture of Autism

    by Thomas Renne, Florian Benitiere, Cecile Poulain, Alma Dubuc, Vincent-Raphael Bourque, Guillaume Huguet, Tomasz J. Nowakowski, Sebastien Jacquemont

    Autism Spectrum Disorders (ASD) can result from rare genetic variants interfering with brain development. Whether their effects converge on specific cortical cell types remains unresolved. Previous studies have focused on a narrow set of high-confidence ASD (hcASD) genes, which were enriched in neuronal cell types during prenatal development. By contrast, studies of postnatal cerebral cortex have repeatedly associated ASD with transcriptional changes in both neurons and glia. To comprehensively map ASD genetic liability across cortical cell types, we conducted a functional genetic burden analysis with 124,416 individuals, including ASD probands and unaffected family members. We examined six classes of rare gene-disrupting variants aggregated across a complete spectrum of transcriptomic cell types of the human prefrontal cortex throughout development. We show that cellular liabilities in ASD delineate a broad and developmentally dynamic architecture. Likewise, we uncover high dependency on classes of variants with Loss-of-Function (LoF) and de novo linked to prenatal cells, while duplications, missense, and inherited variants increase liability through postnatal and glial cell types. Notably, inherited LoF variants uncover the contribution of microglia to ASD liability, also supported by transcriptomic evidence from postmortem ASD brains. Finally, we show that overall, variants disrupting genes differentially expressed in postmortem ASD brains significantly contribute to ASD liability, demonstrating convergence between disrupted transcriptomes and genetic liability. Together, our study offers an integrative, cell-type-aware framework for interpreting ASD risk genetics.

  • Open Access

    Mirror effect of genomic deletions and duplications on cognitive ability across the human cerebral cortex

    by Kuldeep Kumar, Sayeh Kazem, Guillaume Huguet, Worrawat Engchuan, Jakub Kopal, Thomas Renne, Omar Shanta, Bhooma Thiruvahindrapuram, Jeffrey MacDonald, Josephine Mollon, et al.

    Cognitive deficits are common across many neurodevelopmental and psychiatric conditions, including those studied in the current set of PGC-CNV papers. How changes in regional gene expression across the cerebral cortex influence cognitive ability remains unknown. Population variation in gene dosage—which significantly impacts gene expression—represents a unique paradigm to address this question. We developed a cerebral-cortex gene-set burden analysis (CC-GSBA) to associate a trait with genomic deletions and duplications that disrupt genes with similar expression profiles across 180 cortical regions. We performed CC-GSBA across 180 cortical regions to test associations with cognitive ability in 260,000 individuals from general population cohorts. Most cortical gene sets were associated with a decrease in cognitive ability when deleted or duplicated, and this novel approach revealed opposing cortical patterns for the effect sizes of deletions and duplications. These cortical patterns of effect sizes followed the cortical gradient previously characterized at the molecular, cellular, and functional levels. We show that genes with preferential expression in sensorimotor regions demonstrated the largest effect on cognition when deleted. At the opposing end of the cortical gradient, genes with preferential expression in multimodal association regions affected cognition the most when duplicated. These two gene dosage cortical patterns could not be explained by particular cell types, developmental epochs, or genetic constraints, highlighting the fact that the macroscopic network organization of the cerebral cortex is key to understanding the effects of gene dosage on cognitive traits.

  • Open Access

    Determinants of pleiotropy and monotonic gene dosage responses across human traits

    by Sayeh Kazem, Kuldeep Kumar, Guillaume Huguet, Josephine Mollon, Thomas Renne, Laura M Schultz, Emma E M Knowles, Worrawat Engchuan, Omar Shanta, Bhooma Thiruvahindrapuram, et al.

    While pleiotropic effects of gene dosage are of particular relevance for comorbidities observed in the developmental pediatric and psychiatric clinic, the biological processes underlying such pleiotropy remain unknown. We developed a new functional burden analysis (FunBurd) to investigate all CNVs, genome-wide, beyond well-studied recurrent CNVs. In ~500,000 UK-Biobank participants, we tested the association between 43 traits and CNVs disrupting 172 tissue or cell-type gene-sets. CNVs affected all traits. Pleiotropy was correlated with genetic constraint and was higher in the brain compared to non-brain functions, even after normalizing for genetic constraint. The levels of pleiotropy, measured by burden correlation, were similar in deletions and loss-of-function SNVs and higher compared to common variants and duplications. Gene sets under high genetic constraint showed less monotonic gene dosage responses across traits. Even in the absence of a monotonic response, we observed a negative correlation between deletion and duplication effect sizes across most traits. Overall, functional gene sets are preferentially associated with a given trait when either deleted or duplicated, but rarely both.


  • Open Access

    Integrating genomic variants and developmental milestones to predict cognitive and adaptive outcomes in autistic children

    by Vincent-Raphaël Bourque, Zoe Schmilovich, Guillaume Huguet, Jade England, Adeniran Okewole, Cécile Poulain, Thomas Renne, Martineau Jean-Louis, Zohra Saci, Xinhe Zhang, et al.

    Although the first signs of autism are often observed as early as 18-36 months of age, there is a broad uncertainty regarding future development, and clinicians lack predictive tools to identify those who will later be diagnosed with co-occurring intellectual disability (ID). Here, we developed predictive models of ID in autistic children (n=5,633 from three cohorts), integrating different classes of genetic variants alongside developmental milestones. The integrated model yielded an AUC ROC=0.65, with this predictive performance cross-validated and generalised across cohorts. Positive predictive values reached up to 55%, accurately identifying 10% of ID cases. The ability to stratify the probabilities of ID using genetic variants was up to twofold greater in individuals with delayed milestones compared to those with typical development. These findings underscore the potential of models in neurodevelopmental medicine that integrate genomics and clinical observations to predict outcomes and target interventions.

  • Open Access

    Effects of gene dosage on cognitive ability: A function-based association study across brain and non-brain processes

    by Guillaume Huguet, Thomas Renne, Cécile Poulain, Alma Dubuc, Kuldeep Kumar, Sayeh Kazem, Worrawat Engchuan, Omar Shanta, Elise Douard, Catherine Proulx, et al.

    Genomic Copy Number Variants (CNVs) that increase risk for neurodevelopmental disorders are also associated with lower cognitive ability in general population cohorts. Studies have focussed on a small set of recurrent CNVs, but burden analyses suggested that the vast majority of CNVs affecting cognitive ability are too rare to reach variant-level association. As a result, the full range of gene-dosage-sensitive biological processes linked to cognitive ability remains unknown. To investigate this issue, we identified all CNVs >50 kilobases in 258k individuals from 6 general population cohorts with assessments of general cognitive abilities. We performed a CNV-GWAS and functional burden analyses, which tested 6502 gene-sets defined by tissue and cell-type transcriptomics as well as gene ontology disrupted by all rare coding CNVs. CNV-GWAS identified a novel duplication at 2q12.3 associated with higher performance in cognitive ability. Among the 864 gene-sets associated with cognitive ability, only 11% showed significant effects for both deletions and duplication. Accordingly, we systematically observed negative correlations between deletion and duplication effect sizes across all levels of biological observations. We quantified the preferential effects of deletions versus duplication using tagDS, a new normalized metric. Cognitive ability was preferentially affected by cortical, presynaptic, and negative-regulation gene-sets when duplicated. In contrast, preferential effects of deletions were observed for subcortical, post-synaptic, and positive-regulation gene-sets. A large proportion of gene-sets assigned to non-brain organs were associated with cognitive ability due to low tissue specificity genes, which were associated with higher sensitive to haploinsufficiency. Overall, most biological functions associated with cognitive ability are divided into those sensitive to either deletion or duplications.


  • Genome-wide analysis of gene dosage in 24,092 individuals estimates that 10,000 genes modulate cognitive ability

    by Guillaume Huguet, Catherine Schramm, Elise Douard, Petra Tamer, Antoine Main, Pauline Monin, Jade England, Khadije Jizi, Thomas Renne, Myriam Poirier, et al.

    Genomic copy number variants (CNVs) are routinely identified and reported back to patients with neuropsychiatric disorders, but their quantitative effects on essential traits such as cognitive ability are poorly documented. We have recently shown that the effect size of deletions on cognitive ability can be statistically predicted using measures of intolerance to haploinsufficiency. However, the effect sizes of duplications remain unknown. It is also unknown if the effect of multigenic CNVs are driven by a few genes intolerant to haploinsufficiency or distributed across tolerant genes as well. Here, we identified all CNVs > 50 kilobases in 24,092 individuals from unselected and autism cohorts with assessments of general intelligence. Statistical models used measures of intolerance to haploinsufficiency of genes included in CNVs to predict their effect size on intelligence. Intolerant genes decrease general intelligence by 0.8 and 2.6 points of intelligence quotient when duplicated or deleted, respectively. Effect sizes showed no heterogeneity across cohorts. Validation analyses demonstrated that models could predict CNV effect sizes with 78% accuracy. Data on the inheritance of 27,766 CNVs showed that deletions and duplications with the same effect size on intelligence occur de novo at the same frequency. We estimated that around 10,000 intolerant and tolerant genes negatively affect intelligence when deleted, and less than 2% have large effect sizes. Genes encompassed in CNVs were not enriched in any GOterms but gene regulation and brain expression were GOterms overrepresented in the intolerant subgroup. Such pervasive effects on cognition may be related to emergent properties of the genome not restricted to a limited number of biological pathways.